Article
Effects of ERCC2 Lys751Gln (A35931C) and CCND1 (G870A) polymorphism on outcome of advanced-stage squamous cell carcinoma of the head and neck are treatment dependent.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Nov 2011
Zhong Shilong, Nukui Tomoko, Buch Shama, Diergaarde Brenda, Weissfeld Lisa A, Grandis Jennifer, Romkes Marjorie, Weissfeld Joel L
Abstract excerpt
BACKGROUND: Germline variation in DNA damage response may explain variable treatment outcomes in squamous cell carcinoma of the head and neck (SCCHN). By grouping patients according to stage and radiation treatment, we compared SCCHN survival with regard to ERCC2 A35931C (Lys751Gln, rs13181) and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
